» Articles » PMID: 2663695

Natural Course and Response to Interferon of Chronic Hepatitis B Accompanied by Antibody to Hepatitis B E Antigen

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1989 Aug 1
PMID 2663695
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The course of chronic hepatitis B was studied in 30 patients who had antibody to hepatitis e antigen and hepatitis B virus DNA in the serum and hepatitis B core antigen in the liver. Over a 2-year period, no patient experienced a sustained spontaneous remission of disease, and follow-up liver histology revealed worsening of the disease in four patients. After 2 years of observation, 24 patients were allocated randomly to one of two groups: 12 patients served as untreated controls and 12 received recombinant human alpha-interferon-2a in a dose of 9 million units intramuscularly three times weekly for 16 weeks. Patients who remained viremic after 16 weeks received 3 million units three times weekly for an additional 8 weeks. Abnormal amino-transferases and serum hepatitis B virus DNA persisted without appreciable changes in all untreated patients. Hepatitis B virus DNA rapidly became undetectable and serum aminotransferases fell to normal in eight treated patients. After the end of treatment, hepatitis B virus DNA became detectable once again in seven patients, in six of whom a peak of aminotransferases (range: 256 to 850 units per liter) ensued; subsequently, hepatitis B virus DNA disappeared, and serum aminotransferases again fell to normal in two of the seven. Overall, hepatitis B virus DNA was no longer detectable in serum and liver histology improved in three treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.

Wei S, Hu M, Chen H, Xie Q, Wang P, Li H BMC Gastroenterol. 2022; 22(1):387.

PMID: 35978283 PMC: 9387004. DOI: 10.1186/s12876-022-02471-y.


Breakthroughs and challenges in the management of pediatric viral hepatitis.

Nicastro E, Norsa L, Di Giorgio A, Indolfi G, DAntiga L World J Gastroenterol. 2021; 27(20):2474-2494.

PMID: 34092970 PMC: 8160618. DOI: 10.3748/wjg.v27.i20.2474.


Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action.

Yu Y, Wan P, Cao Y, Zhang W, Chen J, Tan L Sci Rep. 2017; 7(1):1729.

PMID: 28496097 PMC: 5431827. DOI: 10.1038/s41598-017-01773-6.


Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up.

Sali S, Alavian S, Foster G, Keyvani H, Mehrnoosh L, Mohammadi N Hepat Mon. 2013; 13(7):e8743.

PMID: 24066002 PMC: 3776148. DOI: 10.5812/hepatmon.8743.


Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety.

Lam Y, Yuen M, Seto W, Lai C Curr Hepat Rep. 2011; 10(4):235-243.

PMID: 22131901 PMC: 3210946. DOI: 10.1007/s11901-011-0109-z.